Market Overview

According to fortune business insights, The global cancer biomarkers market size was valued at USD 42.87 billion in 2025. It is projected to grow from USD 48.2 billion in 2026 to USD 83.61 billion by 2034, exhibiting a CAGR of 7.13% during the forecast period. North America dominated the cancer biomarkers market with a market share of 35.94% in 2025.

The analysis shows that the market is driven by the increasing global incidence of cancer, expanding research, and technological advancements. Cancer biomarkers, which are molecules indicating the presence of cancer, are crucial for early detection, non-invasive diagnosis, personalized medicine, and drug discovery and development. The growing demand for these applications is boosting market growth worldwide.

Major Players Profiled in the Market Report:

• F. Hoffmann-La Roche Ltd.
• Abbott
• Thermo Fisher Scientific
• Bio-Rad Laboratories, Inc.
• CENTOGENE N.V.
• Axon Medchem
• Sino Biological Inc.
• R&D System
• BioVision Inc.
• Myriad RBM
• Other players

Segments

Breast Cancer Segment to Hold Largest Share due to High Prevalence

Based on cancer type, the market is segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, and others. The breast cancer segment is expected to hold the largest market share (32.59% in 2026), driven by its high prevalence, rising awareness, and increasing research activities focused on new detection biomarkers.

HER-2 Biomarker Segment to Dominate the Market

By biomarker type, the market is categorized into PSA, HER-2, EGFR, KRAS, and others. The HER-2 segment is projected to hold the largest share (33.34% in 2026) due to the rising prevalence of breast cancer and the introduction of new biomarker-based tests, such as liquid biopsies, for its diagnosis.